Visitors, including guests, contractors and vendors, to any MCW campus are asked to refrain from coming to campus. Badge-access is required to enter any campus building. All MCW-sponsored site visits or gatherings of more than 10 individuals are cancelled and/or must be rescheduled for a later date. For MCW updates on the COVID-19 pandemic, visit mcw.edu/covid-19.
Dr. Ramchandran began his research career at the Georgia Health Sciences University (formerly called Medical College of Georgia) in Dr. Dorothy Tuan’s laboratory in 1992 where he studied the transcriptional mechanisms controlling hematopoiesis.
He then joined Dr. Vikas Sukhatme’s laboratory in 1997 as a post-doctoral fellow at Beth Israel Deaconess Medical Center, Harvard Medical School. In Dr. Sukhatme’s laboratory he studied the role of basement membrane proteins in endothelial cell growth and the implications of this process for tumor growth. His work at Harvard primarily focused on understanding the mechanisms of angiogenesis, the growth of new blood vessels from pre-existing vessels, and how this process affects tumor growth.
In 2002, he was recruited to the NIH on receipt of the National Cancer Institute Scholar Award, and established his first independent research program studying the developmental mechanisms of vascular biology. In 2007, he joined the Children’s Research Institute (CRI) at the Medical College of Wisconsin where he currently serves on the faculty as a tenured professor in the Department of Pediatrics (DOP).
In the Department of Pediatrics (DOP), he heads the Developmental Vascular Biology Program, and is the Director of the Zebrafish Drug Screening Core in the CRI. In 2008-09, Dr. Ramchandran made a serendipitous discovery that led to the identification of mutations in two genes sucrose non-fermenting related kinase-1 (snrk-1) and dual specific phosphatase-5 (dusp-5) in patients with vascular anomalies.
Since then his research has focused on the role of these genes in both normal and abnormal vascular development process in disease. He has also established a robust drug discovery program that is geared towards identifying small molecules targeting critical gene products responsible for diseases affected by deregulated vascular growth. His research is funded from National Institutes of Health, and Lymphatic Malformation Institute.
He is the Vice Chair for Research in the Department of Obstetrics and Gynecology (OBGYN), which began on October 1, 2013. This position will bridge the clinical problems associated with the mother and the child, and will facilitate the development of the maternal-child health research and gynecological cancer programs in the Department of OBGYN.
Title of Research Study
Awards / Publications / Presentations